宫颈癌（CC）是全球性问题，特别是在低收入和中等收入国家，患者通常被诊断为局部晚期疾病。直到最近，所有化疗药物在铂化合物治疗失败后，对晚期宫颈癌的ORR和12个月整体生存率（12个月OS）都达到了低水平。免疫治疗、靶向治疗和抗体药物联合治疗（ADC）的系统治疗进展已将12个月OS限制提高。最近，免疫治疗（pembrolizumab）已成为先线治疗铂类和紫杉醇治疗中的标准，并在铂类双联治疗失败后成为第二线治疗。Copyright © 2023 Elsevier B.V. All rights reserved.

Cervical cancer (CC) is a worldwide problem, especially in low- and middle-income countries, where patients are often diagnosed with locally advanced disease. Until recently, all chemotherapy drugs achieved low ORR and 12-month overall survival (12- month OS) for advanced CC after failure for platinum compounds. Advances in systemic therapy with immunotherapy, targeted therapy, and antibody-drug conjugates (ADC) have leveraged the 12-month OS limit. Recently, immunotherapy (pembrolizumab) has become the standard of care in first-line advanced CC combined with platinum and taxane and in second-line after platinum doublet failure.Copyright © 2023 Elsevier B.V. All rights reserved.